For the Media
Dr. Brenda Sandmaier is a member of Fred Hutch's Clinical Research Division. Her research is focused on the development conditioning regimens that have minimal toxicity and, thus, allow us to extend the benefit of stem cell transplants to a greater number of patients. Towards that end, we are using a preclinical model and have extended our findings to patients in clinical studies.
Overview of Brenda Sandmaier's Research Focus
Stem cell engraftment in MHC-matched and mismatched transplants: development of nonmyeloablative conditioning regimens
Brenda Sandmaier - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Brenda Sandmaier - Seattle Cancer Care Alliance profile
Dr. Sandmaier is a medical oncologist who treats patients with hematologic malignancies including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome. Her focus of research is in the area of reduced intensity transplantation and the use of alternative donors.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.